First-Line Treatment of Low–Tumor Burden FL: A Randomized Phase III Trial Assessing SC Rituximab
Physician's Weekly,
The following is a summary of “Randomized Phase III Trial Evaluating Subcutaneous Rituximab for the First-Line Treatment of Low–T…
Randomized Phase III Trial Evaluating Subcutaneous Rituximab for the First-Line Treatment of Low–Tumor Burden Follicular Lymphoma: Results of a LYSA Study
Overview of attention for article published in Journal of Clinical Oncology, April 2023
Altmetric Badge
About this Attention Score
-
In the top 25% of all research outputs scored by Altmetric
-
High Attention Score compared to outputs of the same age (93rd percentile)
-
High Attention Score compared to outputs of the same age and source (87th percentile)
Readers on
- mendeley
- 32 Mendeley